KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Long-Term Debt Issuances: 2016-2022

Historic Long-Term Debt Issuances for Halozyme Therapeutics (HALO) over the last 1 years, with Sep 2022 value amounting to $452.0 million.

  • Halozyme Therapeutics' Long-Term Debt Issuances was N/A to $452.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.5 billion, marking a year-over-year change of. This contributed to the annual value of $702.0 million for FY2022, which is 10.56% down from last year.
  • According to the latest figures from Q3 2022, Halozyme Therapeutics' Long-Term Debt Issuances is $452.0 million, which was up 80.80% from $250.0 million recorded in Q2 2022.
  • Over the past 5 years, Halozyme Therapeutics' Long-Term Debt Issuances peaked at $784.9 million during Q1 2021, and registered a low of $250.0 million during Q2 2022.
  • In the last 2 years, Halozyme Therapeutics' Long-Term Debt Issuances had a median value of $452.0 million in 2022 and averaged $495.6 million.